Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

Roivant Sciences·Products & Services·9 segments·Rolls up to R&D

Breakdown

Segment	Q1 '26
Anti-FcRn franchise—endocrine diseases	$26.33M
Anti-FcRn franchise—neurological diseases	$20.80M
Brepocitinib	$14.34M
Other development and discovery programs	$13.43M
Anti-FcRn franchise—rheumatology diseases	$12.86M
Mosliciguat	$9.83M
Anti-FcRn franchise—dermatology diseases	$4.13M
Anti-FcRn franchise—other clinical and nonclinical	$193.00K
Total	$198.95M

Anti-FcRn franchise—contractual costs related to batoclimab program discontinuation is derived from annual filings.

Anti-FcRn franchise—endocrine diseasesView metric

Anti-FcRn franchise—neurological diseasesView metric

Anti-FcRn franchise—rheumatology diseasesView metric

Anti-FcRn franchise—dermatology diseasesView metric

Anti-FcRn franchise—other clinical and nonclinicalView metric

BrepocitinibView metric

Other development and discovery programsView metric

Anti-FcRn franchise—contractual costs related to batoclimab program discontinuationView metric